Badolato, Mariateresa published the artcileTriazolopyrimidinium salts: discovery of a new class of agents for cancer therapy, Recommanded Product: 3-Chlorobenzylchloride, the publication is Future Medicinal Chemistry (2020), 12(5), 387-402, database is CAplus and MEDLINE.
Aim: The [1,2,4]triazolo[1,5-a]pyrimidine core is highly privileged in medicinal chem. due to its versatile pharmacol. activity profile. Recently, the search for novel anticancer agents has focused on [1,2,4]triazolo[1,5-a]pyrimidine derivatives Results: Our hit functionalization has led to the discovery of new [1,2,4]triazolo[1,5-a]pyrimidinium salts with potential anticancer activity. Among a small library of mols., compound 9 significantly inhibits cancer cell growth in a panel of in vitro models. Mol. docking studies and preliminary binding assay have displayed that 9 could directly bind the Src homol. 2 (SH2) domain of STAT3 protein. Conclusion: Compound 9 is a novel promising lead compound that motivates addnl. evaluation of [1,2,4]triazolo[1,5-a]pyrimidinium salts as novel potential chemotherapeutics.
Future Medicinal Chemistry published new progress about 620-20-2. 620-20-2 belongs to chlorides-buliding-blocks, auxiliary class Chloride,Benzyl chloride,Benzene, name is 3-Chlorobenzylchloride, and the molecular formula is C7H6Cl2, Recommanded Product: 3-Chlorobenzylchloride.
Referemce:
https://en.wikipedia.org/wiki/Chloride,
Chlorides – an overview | ScienceDirect Topics